Compare Expensify Inc (EXFY) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs IDEXX Laboratories, Inc. — how do they compare? Expensify Inc trades at $2.39 (market cap $208.82M), while IDEXX Laboratories, Inc. trades at $516.84 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 193.6× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EXFY | IDXX | |
|---|---|---|
Market Cap | $208.82M | $40.43B |
Volume | 456,102 | 692,164 |
Sector | Technology | Health |
52-Week High | $2.72 | $766.68 |
52-Week Low | $0.75 | $504.70 |
Typical Hold Time | 41 Days | 46 Days |
Enterprise Value | $148.44M | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.40, up 5.73% today, showing technical bullish momentum with positive moving averages. The company reported mixed quarterly results with recent beats but maintains negative profitability metrics. Recent business developments include strategic AI integrations and European expansion of its corporate card program, signaling growth initiatives despite ongoing net losses.
The outlook remains speculative with analyst consensus pointing to significant upside potential ($13.75 target) but fundamental challenges persist including negative margins and cash flow volatility. Key risks include execution on AI transition and competitive pressure in expense management software, while institutional sentiment leans bullish with 50% buy ratings.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
